The blood product is only one part of the case. This guide explains how the indication is reviewed, how compatibility is established, what happens during administration, what the team monitors and what follow-up matters.
Cesalpino does not diagnose or issue products directly to pet parents. The treating veterinarian assesses the patient and contacts us through an approved participating practice when transfusion support is indicated.
The recipient pathway
Safe transfusion starts before the line is connected. The team defines the problem, chooses the component, reviews prior exposure, establishes compatibility, plans the dose and records the baseline.
01 — Before transfusion
The treating veterinarian assesses why oxygen delivery, clotting or protein support is inadequate; how quickly the problem is changing; whether bleeding or destruction is continuing; and what treatment is addressing the underlying cause.
02 — Before transfusion
Packed red blood cells support oxygen-carrying capacity. Fresh frozen plasma provides coagulation factors and other plasma proteins. A patient receives the component that addresses the deficit rather than whole blood by default.
03 — Before transfusion
Even a transfusion years ago matters. Previous exposure can lead to antibodies that change compatibility. The date, component, blood type, response and any suspected reaction belong in the patient record.
04 — Before transfusion
Canine donors and recipients are typed for DEA 1. A major cross-match checks recipient plasma against donor red cells; additional testing is selected according to species, history and the clinical situation.
05 — Before transfusion
The veterinarian uses the patient’s weight, current and target red-cell values, clinical status and the component characteristics to plan the transfusion. Rate and total volume are patient-specific and are not copied from a public chart.
06 — Before transfusion
Temperature, pulse, respiratory rate, mucous membranes, mentation, blood pressure where available, PCV or haematocrit and total solids are recorded before administration so subsequent changes can be interpreted.
During administration
The patient is observed closely throughout and after transfusion. Any change is assessed against the pre-transfusion baseline and the underlying disease; a suspected reaction is never dismissed as “just the blood”.
Patient monitoring
A meaningful rise can be the first sign of a febrile reaction, but fever can also come from the underlying disease. The baseline and timing matter.
Patient monitoring
Changes may reflect the patient’s disease, volume status, pain, fever, haemolysis, allergic reaction or circulatory overload and require immediate clinical assessment.
Patient monitoring
Tachypnoea, increased effort, coughing or new oxygen need may signal a reaction, overload or progression of the primary disease.
Patient monitoring
Colour, capillary refill, pulse quality, mentation and extremity temperature help show whether tissue perfusion is improving or deteriorating.
Patient monitoring
Facial swelling, hives, itching, vomiting, diarrhoea or sudden salivation can accompany hypersensitivity and are recorded promptly.
Patient monitoring
Dark urine, red plasma, jaundice, inadequate rise in PCV or an accelerated later decline can suggest red-cell destruction and trigger further investigation.
At the bedside
Compatibility is not the final safety check. Identification, storage, equipment, line use, administration rate, observation and traceability all affect what happens to the patient.
The team verifies the patient, intended component, donor-unit identifier, blood type, compatibility result, expiry, issue conditions and planned volume before connecting the line. The identifiers are copied into the recipient record, not reconstructed later.
The component is checked for label integrity, leaks, clots, unexpected colour, haemolysis or another visible change. Storage and transport history are reviewed. A questionable unit is quarantined rather than used because a patient is waiting.
A suitable intravenous catheter and blood administration set with the appropriate filter are selected for the patient and component. Line patency is confirmed, and incompatible fluids or medicines are not mixed into the blood line.
Administration begins cautiously while the patient is observed closely. The subsequent rate reflects urgency, cardiovascular and renal status, volume tolerance and any change from baseline. There is no single public rate that is safe for every recipient.
Time, component volume, vital signs, examination findings, interruptions, treatment and the person making each observation are recorded contemporaneously. A normal transfusion needs a record just as much as a reaction does.
The team has a defined route to pause or stop administration, maintain venous access, examine the patient, preserve the unit and relevant samples, provide supportive treatment and contact Cesalpino when a reaction is suspected.
Transfusion reactions
Reaction categories overlap and clinical signs are not always specific. The response is to stop or slow administration as appropriate, assess the patient, preserve samples and records, investigate, treat and report.
A temperature rise during or soon after transfusion after other causes are considered. Leukocyte-reduced products can reduce exposure to donor leukocytes and inflammatory mediators, but fever still demands assessment.
May range from skin signs to gastrointestinal, respiratory or circulatory compromise. Administration is paused or stopped while the patient is examined and treatment is selected.
Incompatible or damaged red cells may be destroyed. Fever, tachycardia, hypotension, pigment changes and an inadequate PCV response are among the concerns. This is an emergency.
Patients with cardiac, renal or severe systemic disease may not tolerate volume well. Respiratory change, blood pressure and fluid balance are watched, and the plan is adjusted to the individual.
A rare but serious possibility addressed through donor screening, aseptic collection, controlled processing, storage and careful evaluation of any abrupt systemic deterioration.
Accelerated loss of transfused red cells or other delayed effects may become apparent after discharge. A falling PCV, recurrent pallor, weakness, fever, jaundice or dark urine warrants veterinary review.
After the transfusion
The team reassesses the clinical signs that led to transfusion and repeats relevant measurements. A red-cell recipient may have PCV or haematocrit checked; a plasma recipient is assessed against the bleeding or coagulation problem being treated.
Before discharge, the family receives specific return precautions. The transfusion record should travel with the patient for life because a future clinician needs to know the exposure and any suspected reaction.
Recipient questions
These answers explain the service boundary and the patient pathway.
No. Requests come from the treating registered veterinarian at an approved participating practice. The veterinarian retains responsibility for the decision to transfuse and for the patient.
No. Compatibility testing reduces important immunological risks, but it cannot prevent every febrile, allergic, volume-related, infectious or non-immune reaction. Monitoring remains essential.
A transfusion supports the patient while the underlying cause is treated. Some patients need one component once; others need repeated assessment or further transfusion. Response is judged clinically and with follow-up testing.
Every dog in an enrolled donor household receives priority access to a compatible product. The treating veterinarian still makes the request, and release depends on clinical suitability and availability.
That your dog has been transfused. Keep the date, component, blood type, donor-unit information, cross-match result and any reaction record. Previous exposure changes future compatibility planning.
For treating veterinarians
Practices are evaluated for participation before product requests are accepted. Registration covers veterinary credentials, transfusion capability, handling, monitoring, reaction reporting and the communication route for urgent cases.